Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury

Circulation Research

Volumn 91, Issue 8, 2002, Pages 696-703

  Mason, Justin C ^a   Ahmed, Zahra ^a   Mankoff, Rivka ^a   Lidington, Elaine A ^a   Ahmad, Saifur ^a   Bhatia, Vinay ^a   Kinderlerer, Anne ^a   Randi, Anna M ^a   Haskard, Dorian O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Atorvastatin; Complement; Cytoprotection; Endothelium

Indexed keywords

ATORVASTATIN; COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; MESSENGER RNA; MEVALONIC ACID; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C ALPHA; SIMVASTATIN; SQUALENE; STATIN; UNCLASSIFIED DRUG;

AORTA; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CELL FUNCTION; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HEART INFARCTION; HUMAN; HUMAN CELL; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; STEADY STATE; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD55; CELL LINE; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C3; CYTOPROTECTION; DITERPENES; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; NITRIC OXIDE; POLYISOPRENYL PHOSPHATES; PROTEIN KINASE C; PYRROLES; RHO GTP-BINDING PROTEINS; RNA, MESSENGER; SIMVASTATIN; UP-REGULATION;

EID: 0037131289     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000038151.57577.19     Document Type: Article

References (41)

1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7-22.
3. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
4. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA. 2001;285:1711-1718.
5. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
6. Casey PJ. Protein lipidabon in cell signaling. Science. 1995;268:221-225.
7. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
8. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
9. Essig M, Nguyen G, Prie D, Escoubet B, Sraer J-D, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins. Circ Res. 1998;83:683-690.
10. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999;19:2894-2900
11. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999;340:115-126.
12. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol. 1999;36:949-955.
13. Torzewski J, Bowyer DE, Waltenberger J, Fitzsimmons C. Processes in atherogenesis: Complement activation. Atherosclerosis. 1997;132:131-138.
14. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-1051.
15. Tedesco F, Fischetti F, Pausa M, Dobrina A, Sim RB, Daha MR. Complement-endothelial cell interactions: Pathophysiological implications. Mol Immunol. 1999:36:261-268.
16. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system, Adv Immunol. 1996;61:201-283.
17. Lublin DM, Atkinson JP, Decay-accelerating factor: Biochemistry, molecular biology and function. Annu Rev Immunol. 1989;7:35-58.
18. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood. 1999;94:1673-1682.
19. Lidington EA, Haskard DO, Mason JC. Induction of decay accelerating factor by thrombin through a protease-activated receptor1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood. 2000;96:2784-2792.
20. Mason JC, Lidington EA, Yarwood H, Lublin DM. Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: A mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum. 2001;44:138-150.
21. Mason JC, Lidington EA, Ahmad SR, Haskard DO. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor upregulation. Am J Physiol. 2002;282:C578-C587.
22. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, Miwa T, Madaio MP, Song W-C. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol. 2001;167:2791-2797.
23. Lin F, Emancipator SN, Salant DJ, Medof ME. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest. 2002;82:563-569.
24. Mason JC, Yarwood H, Támok A, Sugars K, Harrison AA, Robinson PJ, Haskard DO. Human Thy-1 is cytokine inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C. J Immunol. 1996;157:874-883.
25. Andoh A, Kinoshita K. Rosenberg I, Podolsky DK. Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol. 2001;167:3887-3893.
26. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
27. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271.
28. Ren S, Shatadal S, Shen GX. Protein kinase C-β mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells. Am J Physiol. 2000;278:E656-E662.
29. Eichholtz T, de Bont D, de Widt J, Liskamp R, Ploegh H. A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem. 1993;268:1982-1986.
30. Cilla DD, Whitfield LR, Gibson DM. Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pbarmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996:60:687-695.
31. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Phammcol Ther. 1999;84:413-428.
32. Ledoux S, Laouari D, Essig M, Runembert I, Trugnan G, Michel JB, Friedlander G. Lovastatin enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells: Implication of Rho-family GTPases, Circ Res. 2002;90:420-427.
33. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
34. Slater SJ, Seiz JL, Staghano BA, Stubbs CD. Interaction of protein kinase C isozymes with Rho GTPases. Biochemistry, 2001;40:4437-4445.
35. Brandt D, Gimona M, Hillmann M, Haller H, Mischak H. Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway. J Biol Chem. 2002;277:20903-20910.
36. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. 1985;57:163-177.
37. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369-378.
38. Niculescu F, Rus HG, Vlaicu R. Decay-accelerating factor regulates complement-mediated damage in the human atherosclerotic wall. Immunol. Lett. 1990;26:17-23.
39. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. 1989;9:802-811.
40. Seifert PS, Hansson GIC Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest. 1989;84:597-604.
41. Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1214-1219.